{"id":6928,"date":"1970-01-01T00:00:00","date_gmt":"1970-01-01T00:00:00","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-resultats-financiers-du-premier-semestre-2012\/"},"modified":"1970-01-01T00:00:00","modified_gmt":"1970-01-01T00:00:00","slug":"nicox-resultats-financiers-du-premier-semestre-2012","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2012\/","title":{"rendered":"Nicox : R\u00e9sultats financiers du premier semestre 2012"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"<p>Au cours des six premiers mois de l\u2019ann\u00e9e 2012, Nicox a r\u00e9alis\u00e9 des progr\u00e8s significatifs dans sa strat\u00e9gie visant \u00e0<br \/>\ndevenir un acteur international sp\u00e9cialis\u00e9 en ophtalmologie, centr\u00e9 sur le d\u00e9veloppement de candidats \u00e0 un stade<br \/>\navanc\u00e9 et sur la commercialisation de produits, \u00bb a d\u00e9clar\u00e9 Michele Garufi, Pr\u00e9sident Directeur G\u00e9n\u00e9ral de Nicox.<br \/>\n\u00ab La premi\u00e8re \u00e9tape a consist\u00e9 en l\u2019acquisition aupr\u00e8s de RPS\u00ae des droits mondiaux d\u2019un portefeuille prometteur de<br \/>\ntests diagnostiques oculaires. Nous pr\u00e9voyons de commercialiser d\u2019ici la fin de l\u2019ann\u00e9e 2012 AdenoPlus\u2122, notre premier<br \/>\nproduit sur le march\u00e9, sous la direction de Jerry St. Peter aux Etats-Unis et de Philippe Masquida en Europe. Nos<br \/>\ndiscussions progressent en vue d\u2019enrichir notre portefeuille de produits aux Etats-Unis et en Europe via d\u2019autres<br \/>\nacquisitions et prises de licences. \u00bb<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-6928","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox : R\u00e9sultats financiers du premier semestre 2012 - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2012\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox : R\u00e9sultats financiers du premier semestre 2012 - Nicox\" \/>\n<meta property=\"og:description\" content=\"Au cours des six premiers mois de l\u2019ann\u00e9e 2012, Nicox a r\u00e9alis\u00e9 des progr\u00e8s significatifs dans sa strat\u00e9gie visant \u00e0 devenir un acteur international sp\u00e9cialis\u00e9 en ophtalmologie, centr\u00e9 sur le d\u00e9veloppement de candidats \u00e0 un stade avanc\u00e9 et sur la commercialisation de produits, \u00bb a d\u00e9clar\u00e9 Michele Garufi, Pr\u00e9sident Directeur G\u00e9n\u00e9ral de Nicox. \u00ab La premi\u00e8re \u00e9tape a consist\u00e9 en l\u2019acquisition aupr\u00e8s de RPS\u00ae des droits mondiaux d\u2019un portefeuille prometteur de tests diagnostiques oculaires. Nous pr\u00e9voyons de commercialiser d\u2019ici la fin de l\u2019ann\u00e9e 2012 AdenoPlus\u2122, notre premier produit sur le march\u00e9, sous la direction de Jerry St. Peter aux Etats-Unis et de Philippe Masquida en Europe. Nos discussions progressent en vue d\u2019enrichir notre portefeuille de produits aux Etats-Unis et en Europe via d\u2019autres acquisitions et prises de licences. \u00bb\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2012\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"1970-01-01T00:00:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-resultats-financiers-du-premier-semestre-2012\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-resultats-financiers-du-premier-semestre-2012\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox : R\u00e9sultats financiers du premier semestre 2012\",\"datePublished\":\"1970-01-01T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-resultats-financiers-du-premier-semestre-2012\\\/\"},\"wordCount\":7,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-resultats-financiers-du-premier-semestre-2012\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-resultats-financiers-du-premier-semestre-2012\\\/\",\"name\":\"Nicox : R\u00e9sultats financiers du premier semestre 2012 - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"1970-01-01T00:00:00+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-resultats-financiers-du-premier-semestre-2012\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox : R\u00e9sultats financiers du premier semestre 2012 - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2012\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox : R\u00e9sultats financiers du premier semestre 2012 - Nicox","og_description":"Au cours des six premiers mois de l\u2019ann\u00e9e 2012, Nicox a r\u00e9alis\u00e9 des progr\u00e8s significatifs dans sa strat\u00e9gie visant \u00e0 devenir un acteur international sp\u00e9cialis\u00e9 en ophtalmologie, centr\u00e9 sur le d\u00e9veloppement de candidats \u00e0 un stade avanc\u00e9 et sur la commercialisation de produits, \u00bb a d\u00e9clar\u00e9 Michele Garufi, Pr\u00e9sident Directeur G\u00e9n\u00e9ral de Nicox. \u00ab La premi\u00e8re \u00e9tape a consist\u00e9 en l\u2019acquisition aupr\u00e8s de RPS\u00ae des droits mondiaux d\u2019un portefeuille prometteur de tests diagnostiques oculaires. Nous pr\u00e9voyons de commercialiser d\u2019ici la fin de l\u2019ann\u00e9e 2012 AdenoPlus\u2122, notre premier produit sur le march\u00e9, sous la direction de Jerry St. Peter aux Etats-Unis et de Philippe Masquida en Europe. Nos discussions progressent en vue d\u2019enrichir notre portefeuille de produits aux Etats-Unis et en Europe via d\u2019autres acquisitions et prises de licences. \u00bb","og_url":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2012\/","og_site_name":"Nicox","article_published_time":"1970-01-01T00:00:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2012\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2012\/"},"author":{"name":"","@id":""},"headline":"Nicox : R\u00e9sultats financiers du premier semestre 2012","datePublished":"1970-01-01T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2012\/"},"wordCount":7,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2012\/","url":"https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2012\/","name":"Nicox : R\u00e9sultats financiers du premier semestre 2012 - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"1970-01-01T00:00:00+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-resultats-financiers-du-premier-semestre-2012\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/6928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=6928"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/6928\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=6928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=6928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=6928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}